Browsing Tag
BEXSERO
2 posts
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
GSK secures FDA approval for 5-in-1 meningococcal vaccine to expand protection for adolescents
GSK has received approval from the US Food and Drug Administration (FDA) for PENMENVY, a 5-in-1 meningococcal vaccine…